Abstract:Histone methyltransferases of the nuclear receptor-binding SET domain protein (NSD) family, including NSD1, NSD2 and NSD3, have crucial roles in chromatin regulation and are implicated in oncogenesis<a href="/articles/s41586-020-03069-8#ref-CR1">1</a>,<a href="/articles/s41586-020-03069-8#ref-CR2">2</a>. NSD enzymes exhibit an autoinhibitory state that is relieved by binding to nucleosomes, enabling dimethylation of histone H3 at Lys36 (H3K36)<a href="#ref-CR3">3</a>,<a href="#ref-CR4">4</a>,<a href="#ref-CR5">5</a>,<a href="#ref-CR6">6</a>,<a href="/articles/s41586-020-03069-8#ref-CR7">7</a>. However, the molecular basis that underlies this mechanism is largely unknown. Here we solve the cryo-electron microscopy structures of NSD2 and NSD3 bound to mononucleosomes. We find that binding of NSD2 and NSD3 to mononucleosomes causes DNA near the linker region to unwrap, which facilitates insertion of the catalytic core between the histone octamer and the unwrapped segment of DNA. A network of DNA- and histone-specific contacts between NSD2 or NSD3 and the nucleosome precisely defines the position of the enzyme on the nucleosome, explaining the specificity of methylation to H3K36. Intermolecular contacts between NSD proteins and nucleosomes are altered by several recurrent cancer-associated mutations in NSD2 and NSD3. NSDs that contain these mutations are catalytically hyperactive in vitro and in cells, and their ectopic expression promotes the proliferation of cancer cells and the growth of xenograft tumours. Together, our research provides molecular insights into the nucleosome-based recognition and histone-modification mechanisms of NSD2 and NSD3, which could lead to strategies for therapeutic targeting of proteins of the NSD family.

Identification of Novel Hits of the NSD1 SET Domain by NMR Fragment-Based Screening

Covalent inhibition of NSD1 histone methyltransferase

Discovery of potent small molecule inhibitors of histone lysine methyltransferase NSDs

The Structure of NSD1 Reveals an Autoregulatory Mechanism Underlying Histone H3K36 Methylation

Identification of Novel Potent NSD2-PWWP1 Ligands Using Structure-Based Design and Computational Approaches

Molecular basis of nucleosomal H3K36 methylation by NSD methyltransferases

Discovery of Novel Disruptor of Silencing Telomeric 1-Like (DOT1L) Inhibitors Using a Target-Specific Scoring Function for the (S)-Adenosyl-l-methionine (Sam)-Dependent Methyltransferase Family.

Target validation and structure-based virtual screening to Discover potential lead molecules against the oncogenic NSD1 histone methyltransferase

Discovery of a Potent and Selective Targeted NSD2 Degrader for the Reduction of H3K36me2

Structure-Based Discovery of a Series of NSD2-PWWP1 Inhibitors

Discovery of a Highly Potent and Selective Inhibitor Targeting Protein Lysine Methyltransferase NSD2

NSD3: Advances in cancer therapeutic potential and inhibitors research

The Target of the NSD Family of Histone Lysine Methyltransferases Depends on the Nature of the Substrate

NSD Family Proteins: Rising Stars As Therapeutic Targets

Discovery of LLC0424 as a Potent and Selective in Vivo NSD2 PROTAC Degrader

Discovery of Small-Molecule Antagonists of the PWWP Domain of NSD2

Structural insights into the C-terminus of the histone-lysine N-methyltransferase NSD3 by small-angle X-ray scattering

The Methyltransferase NSD3 Has Chromatin-binding Motifs, PHD5-C5HCH, That Are Distinct from Other NSD (nuclear Receptor SET Domain) Family Members in Their Histone H3 Recognition*

Prospect of targeting lysine methyltransferase NSD3 for tumor therapy

Unveiling the potential of phytochemicals to inhibit nuclear receptor binding SET domain protein 2 for cancer: Pharmacophore screening, molecular docking, ADME properties, and molecular dynamics simulation investigations

Conformational-Design-Driven Discovery of EZM0414: A Selective, Potent SETD2 Inhibitor for Clinical Studies